AI Analysis
AI-generated analysis. Always verify with the original filing.
60 Degrees Pharmaceuticals achieved revenue growth in FY2025, but continued operating losses and cash burn highlight ongoing challenges in achieving sustainable profitability despite improved sales dynamics.
Key Takeaways
1Revenue increased 65.5% to $1.0M, driven by higher product sales, price increases, and fewer returns despite a shortage of Arakoda 16-ct boxes during the year.
2Gross profit rose slightly to $223.8K with a margin of 22.3%, though cost of revenues grew due to higher sales volume and inventory write-offs before expiration.
3Operating income improved to -$7.8M from -$9.7M year-over-year, reflecting lower cash outflows despite continued high operating expenses.
4Net loss narrowed to -$7.4M from -$7.9M, with diluted EPS improving to -$11.73 from -$18.55, signaling reduced per-share losses despite negative earnings trajectory.
5Free cash flow was -$7.0M, worse than operating cash flow of -$6.8M after accounting for $140K in capital expenditures, showing sustained cash consumption.